A carregar...
BAFF inhibition in SLE – is tolerance restored?
The B cell activating factor (BAFF) inhibitor, belimumab, is the first biologic drug approved for the treatment of SLE, and exhibits modest, but durable, efficacy in decreasing disease flares and organ damage. BAFF and its homolog APRIL are TNF-like cytokines that support the survival and differenti...
Na minha lista:
| Publicado no: | Immunol Rev |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6935406/ https://ncbi.nlm.nih.gov/pubmed/31562657 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/imr.12810 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|